Citius Oncology
CTOR
15 hedge funds and large institutions have $34.3M invested in Citius Oncology in 2022 Q4 according to their latest regulatory filings, with 15 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
37.77% more ownership
Funds ownership: 0% → 37.77% (+38%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$5.07M |
| 2 |
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$4.06M |
| 3 |
Glazer Capital LLC
New York
|
+$3.92M |
| 4 |
Weiss Asset Management
Boston,
Massachusetts
|
+$3.55M |
| 5 |
Mizuho Securities USA
New York
|
+$3.07M |
Top Sellers
CTOR Hedge Fund Activity: Q4 2022 in Review
15 of the 6,242 institutional investors tracked by Wall St. Rank reported a position in Citius Oncology (CTOR) for Q4 2022, worth a combined $34.3M.
Buyers outnumbered sellers: 15 funds opened new CTOR positions and 0 closed out — a net gain of 15 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Hudson Bay Capital Management, opening a new position worth an estimated $5.07M.
- 15 institutional investors held Citius Oncology (CTOR) as of Q4 2022, up from 0 in Q3 2022.
- Funds reported $34.3M of Citius Oncology stock for Q4 2022.
- 15 funds opened new Citius Oncology positions in Q4 2022 and 0 closed out, a net change of +15 holders.
- The largest Citius Oncology buyer in Q4 2022 was Hudson Bay Capital Management, an estimated $5.07M added.
Based on aggregated 13F filings for Q4 2022.